These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17594092)

  • 1. Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed.
    Min SH; Goldman ID; Zhao R
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):819-27. PubMed ID: 17594092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways.
    Yang TY; Chang GC; Chen KC; Hung HW; Hsu KH; Wu CH; Sheu GT; Hsu SL
    Mol Carcinog; 2013 Mar; 52(3):183-94. PubMed ID: 22086658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts.
    Tedeschi PM; Kathari YK; Farooqi IN; Bertino JR
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1029-32. PubMed ID: 25205429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability.
    Chattopadhyay S; Tamari R; Min SH; Zhao R; Tsai E; Goldman ID
    Oncologist; 2007 Jul; 12(7):808-15. PubMed ID: 17673612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.
    Cameron RB; Hou D
    J Thorac Cardiovasc Surg; 2013 Feb; 145(2):496-504. PubMed ID: 23174177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinogen-induced S-phase arrest is Chk1 mediated and caffeine sensitive.
    Guo N; Faller DV; Vaziri C
    Cell Growth Differ; 2002 Feb; 13(2):77-86. PubMed ID: 11864911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
    Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
    Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.
    O'Kane SL; Eagle GL; Greenman J; Lind MJ; Cawkwell L
    Lung Cancer; 2010 Feb; 67(2):160-5. PubMed ID: 19450893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
    Giovannetti E; Zucali PA; Assaraf YG; Leon LG; Smid K; Alecci C; Giancola F; Destro A; Gianoncelli L; Lorenzi E; Roncalli M; Santoro A; Peters GJ
    Br J Cancer; 2011 Nov; 105(10):1542-53. PubMed ID: 21970874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A molecular targeting against nuclear factor-κB, as a chemotherapeutic approach for human malignant mesothelioma.
    Nishikawa S; Tanaka A; Matsuda A; Oida K; Jang H; Jung K; Amagai Y; Ahn G; Okamoto N; Ishizaka S; Matsuda H
    Cancer Med; 2014 Apr; 3(2):416-25. PubMed ID: 24510578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pemetrexed: from preclinic to clinic].
    Lansiaux A; Lokiec F
    Bull Cancer; 2007; 94 Spec No Actualites():S134-8. PubMed ID: 17845983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling.
    Goldstein M; Roos WP; Kaina B
    Toxicol Appl Pharmacol; 2008 May; 229(1):20-32. PubMed ID: 18289623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation.
    Alao JP; Sunnerhagen P
    Radiat Oncol; 2009 Nov; 4():51. PubMed ID: 19903334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosensitization of tumor cells by modulation of ATM kinase.
    Choi EK; Ji IM; Lee SR; Kook YH; Griffin RJ; Lim BU; Kim JS; Lee DS; Song CW; Park HJ
    Int J Radiat Biol; 2006 Apr; 82(4):277-83. PubMed ID: 16690595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.